Loading…
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells
In addition to the mutational status of KRAS, the epidermal growth factor receptor (EGFR) ligands amphiregulin (AREG) and epiregulin (EREG) might function as bona fide biomarkers of cetuximab (Ctx) sensitivity for most EGFR-driven carcinomas. Lentivirus-delivered small hairpin RNAs were employed to...
Saved in:
| Published in: | British journal of cancer 2012-04, Vol.106 (8), p.1406-1414 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c440t-1ebff41b7fbfc0220ebf92b9878d74c0b4f914c6ba06ec31a20142e2802876c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c440t-1ebff41b7fbfc0220ebf92b9878d74c0b4f914c6ba06ec31a20142e2802876c3 |
| container_end_page | 1414 |
| container_issue | 8 |
| container_start_page | 1406 |
| container_title | British journal of cancer |
| container_volume | 106 |
| creator | OLIVERAS-FERRAROS, C CUFI, S QUERALT, B VAZQUEZ-MARTIN, A MARTIN-CASTILLO, B DE LLORENS, R BOSCH-BARRERA, J BRUNET, J MENENDEZ, J. A |
| description | In addition to the mutational status of KRAS, the epidermal growth factor receptor (EGFR) ligands amphiregulin (AREG) and epiregulin (EREG) might function as bona fide biomarkers of cetuximab (Ctx) sensitivity for most EGFR-driven carcinomas.
Lentivirus-delivered small hairpin RNAs were employed to specifically reduce AREG or EREG gene expression in wild-type KRAS A431 squamous cell carcinoma cells. Colony-forming assays were used to monitor the impact of AREG and EREG knockdown on Ctx efficacy. Amphiregulin and EREG protein expression levels were assessed by quantitative ELISA in parental A431 cells and in pooled populations of A431 cells adapted to grow in the presence of Ctx. A phosphoproteomic platform was used to measure the relative level of phosphorylation of 42 distinct receptor tyrosine kinases before and after the acquisition of resistance to Ctx.
Stable gene silencing of either ligand was found to notably reduce the expression of the other ligand. Parental A431 cells with normal expression levels of AREG/EREG exhibited significantly increased growth inhibition in response to Ctx, compared with derivatives that are engineered to produce minimal AREG/EREG. The parental A431 cells acutely treated with Ctx exhibited reduced basal expression levels of AREG/EREG. Pooled populations of Ctx-resistant A431 cells expressed significantly lower levels of AREG/EREG and were insensitive to the downregulatory effects of Ctx. Phosphoproteomic screen identified a remarkable hyperactivation of FGFR3 in Ctx-resistant A431 cells, which gained sensitivity to the cytotoxic and apoptotic effects of the FGFR3 TK inhibitor PD173074. The A431 parental cells acutely treated with Ctx rapidly activated FGFR3 and their concomitant exposure to Ctx and PD173074 resulted in synergistic apoptosis.
Cross-suppression of AREG/EREG expression may explain the tight co-expression of AREG and EREG, as well as their tendency to be more highly expressed than other EGFR ligands to determine Ctx efficacy. The positive selection for Ctx-resistant tumour cells exhibiting AREG/EREG cross-suppression may have an important role in the emergence of Ctx resistance. As de-repression of FGFR3 activity rapidly replaces the loss of EGFR-ligand signalling in terms of cell proliferation and survival, combinations of Ctx and FGFR3-targeted drugs may be a valuable strategy to enhance the efficacy of single Ctx while preventing or delaying acquired resistance to Ctx. |
| doi_str_mv | 10.1038/bjc.2012.103 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3326676</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>993912663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-1ebff41b7fbfc0220ebf92b9878d74c0b4f914c6ba06ec31a20142e2802876c3</originalsourceid><addsrcrecordid>eNpdkUtv1DAUhS0EokNhxxpZSIgNKX5NHhukatQpFZUqle4t23FSj5w42DHQH8T_5IZOS9tVdOLvHp17D0JvKTmihNef9c4cMULZop6hFV1zVtCaVc_RihBSFaRh5AC9SmkHsiF19RIdMCYaKhhboT-bGFIqUp6maFNyYcShwyen20vsXa_GNmE1TNcu2j57N2L4g-30SLa2iPbh9BamOU6uH5UHqMcmjHN0Os8WzwEbO-ffblAaw4xLsxqNxeD1y_m2mG8mi79dHn_Hcx5CjkB7n16jF53yyb7Zfw_R1fbkavO1OL84PdscnxdGCDIX1OquE1RXne4MYYyAbphu6qpuK2GIFh2sbUqtSGkNpwruJphlNWF1VRp-iL7c2k5ZD7Y1FmIrL6cIaeONDMrJxy-ju5Z9-Ck5Z2VZlWDwcW8Qw49s0ywHl5YN1GhDTrJpeEMB5UC-f0LuYFs42D-IirUoGUCfbiGzlBRtdx-FErmUL6F8uZS_KMDfPYx_D9-1DcCHPaCSUb6LcHqX_nPrmpFyXfG_Ysa7KQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>993145462</pqid></control><display><type>article</type><title>Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells</title><source>PubMed Central (PMC)</source><creator>OLIVERAS-FERRAROS, C ; CUFI, S ; QUERALT, B ; VAZQUEZ-MARTIN, A ; MARTIN-CASTILLO, B ; DE LLORENS, R ; BOSCH-BARRERA, J ; BRUNET, J ; MENENDEZ, J. A</creator><creatorcontrib>OLIVERAS-FERRAROS, C ; CUFI, S ; QUERALT, B ; VAZQUEZ-MARTIN, A ; MARTIN-CASTILLO, B ; DE LLORENS, R ; BOSCH-BARRERA, J ; BRUNET, J ; MENENDEZ, J. A</creatorcontrib><description>In addition to the mutational status of KRAS, the epidermal growth factor receptor (EGFR) ligands amphiregulin (AREG) and epiregulin (EREG) might function as bona fide biomarkers of cetuximab (Ctx) sensitivity for most EGFR-driven carcinomas.
Lentivirus-delivered small hairpin RNAs were employed to specifically reduce AREG or EREG gene expression in wild-type KRAS A431 squamous cell carcinoma cells. Colony-forming assays were used to monitor the impact of AREG and EREG knockdown on Ctx efficacy. Amphiregulin and EREG protein expression levels were assessed by quantitative ELISA in parental A431 cells and in pooled populations of A431 cells adapted to grow in the presence of Ctx. A phosphoproteomic platform was used to measure the relative level of phosphorylation of 42 distinct receptor tyrosine kinases before and after the acquisition of resistance to Ctx.
Stable gene silencing of either ligand was found to notably reduce the expression of the other ligand. Parental A431 cells with normal expression levels of AREG/EREG exhibited significantly increased growth inhibition in response to Ctx, compared with derivatives that are engineered to produce minimal AREG/EREG. The parental A431 cells acutely treated with Ctx exhibited reduced basal expression levels of AREG/EREG. Pooled populations of Ctx-resistant A431 cells expressed significantly lower levels of AREG/EREG and were insensitive to the downregulatory effects of Ctx. Phosphoproteomic screen identified a remarkable hyperactivation of FGFR3 in Ctx-resistant A431 cells, which gained sensitivity to the cytotoxic and apoptotic effects of the FGFR3 TK inhibitor PD173074. The A431 parental cells acutely treated with Ctx rapidly activated FGFR3 and their concomitant exposure to Ctx and PD173074 resulted in synergistic apoptosis.
Cross-suppression of AREG/EREG expression may explain the tight co-expression of AREG and EREG, as well as their tendency to be more highly expressed than other EGFR ligands to determine Ctx efficacy. The positive selection for Ctx-resistant tumour cells exhibiting AREG/EREG cross-suppression may have an important role in the emergence of Ctx resistance. As de-repression of FGFR3 activity rapidly replaces the loss of EGFR-ligand signalling in terms of cell proliferation and survival, combinations of Ctx and FGFR3-targeted drugs may be a valuable strategy to enhance the efficacy of single Ctx while preventing or delaying acquired resistance to Ctx.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2012.103</identifier><identifier>PMID: 22491422</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Amphiregulin ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents - pharmacology ; Apoptosis - drug effects ; Biological and medical sciences ; Biomarkers ; Cancer research ; Cell Survival - drug effects ; Cetuximab ; Drug Resistance, Neoplasm - drug effects ; EGF Family of Proteins ; Epidermal growth factor ; Epidermal Growth Factor - antagonists & inhibitors ; Epidermal Growth Factor - biosynthesis ; Epidermal Growth Factor - genetics ; Epiregulin ; Gene expression ; Gene Knockdown Techniques ; Glycoproteins - antagonists & inhibitors ; Glycoproteins - biosynthesis ; Glycoproteins - genetics ; Humans ; Intercellular Signaling Peptides and Proteins - biosynthesis ; Intercellular Signaling Peptides and Proteins - genetics ; Kinases ; Ligands ; Medical research ; Medical sciences ; Metastasis ; Oncology ; Pyrimidines - pharmacology ; Receptor, Epidermal Growth Factor - metabolism ; Receptor, Fibroblast Growth Factor, Type 3 - metabolism ; Short Communication ; Signal Transduction - drug effects ; Skin Neoplasms - drug therapy ; Skin Neoplasms - pathology ; Structure-Activity Relationship ; Tumor Cells, Cultured ; Tumors</subject><ispartof>British journal of cancer, 2012-04, Vol.106 (8), p.1406-1414</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Apr 10, 2012</rights><rights>Copyright © 2012 Cancer Research UK 2012 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-1ebff41b7fbfc0220ebf92b9878d74c0b4f914c6ba06ec31a20142e2802876c3</citedby><cites>FETCH-LOGICAL-c440t-1ebff41b7fbfc0220ebf92b9878d74c0b4f914c6ba06ec31a20142e2802876c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326676/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326676/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25820657$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22491422$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OLIVERAS-FERRAROS, C</creatorcontrib><creatorcontrib>CUFI, S</creatorcontrib><creatorcontrib>QUERALT, B</creatorcontrib><creatorcontrib>VAZQUEZ-MARTIN, A</creatorcontrib><creatorcontrib>MARTIN-CASTILLO, B</creatorcontrib><creatorcontrib>DE LLORENS, R</creatorcontrib><creatorcontrib>BOSCH-BARRERA, J</creatorcontrib><creatorcontrib>BRUNET, J</creatorcontrib><creatorcontrib>MENENDEZ, J. A</creatorcontrib><title>Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>In addition to the mutational status of KRAS, the epidermal growth factor receptor (EGFR) ligands amphiregulin (AREG) and epiregulin (EREG) might function as bona fide biomarkers of cetuximab (Ctx) sensitivity for most EGFR-driven carcinomas.
Lentivirus-delivered small hairpin RNAs were employed to specifically reduce AREG or EREG gene expression in wild-type KRAS A431 squamous cell carcinoma cells. Colony-forming assays were used to monitor the impact of AREG and EREG knockdown on Ctx efficacy. Amphiregulin and EREG protein expression levels were assessed by quantitative ELISA in parental A431 cells and in pooled populations of A431 cells adapted to grow in the presence of Ctx. A phosphoproteomic platform was used to measure the relative level of phosphorylation of 42 distinct receptor tyrosine kinases before and after the acquisition of resistance to Ctx.
Stable gene silencing of either ligand was found to notably reduce the expression of the other ligand. Parental A431 cells with normal expression levels of AREG/EREG exhibited significantly increased growth inhibition in response to Ctx, compared with derivatives that are engineered to produce minimal AREG/EREG. The parental A431 cells acutely treated with Ctx exhibited reduced basal expression levels of AREG/EREG. Pooled populations of Ctx-resistant A431 cells expressed significantly lower levels of AREG/EREG and were insensitive to the downregulatory effects of Ctx. Phosphoproteomic screen identified a remarkable hyperactivation of FGFR3 in Ctx-resistant A431 cells, which gained sensitivity to the cytotoxic and apoptotic effects of the FGFR3 TK inhibitor PD173074. The A431 parental cells acutely treated with Ctx rapidly activated FGFR3 and their concomitant exposure to Ctx and PD173074 resulted in synergistic apoptosis.
Cross-suppression of AREG/EREG expression may explain the tight co-expression of AREG and EREG, as well as their tendency to be more highly expressed than other EGFR ligands to determine Ctx efficacy. The positive selection for Ctx-resistant tumour cells exhibiting AREG/EREG cross-suppression may have an important role in the emergence of Ctx resistance. As de-repression of FGFR3 activity rapidly replaces the loss of EGFR-ligand signalling in terms of cell proliferation and survival, combinations of Ctx and FGFR3-targeted drugs may be a valuable strategy to enhance the efficacy of single Ctx while preventing or delaying acquired resistance to Ctx.</description><subject>Amphiregulin</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Cancer research</subject><subject>Cell Survival - drug effects</subject><subject>Cetuximab</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>EGF Family of Proteins</subject><subject>Epidermal growth factor</subject><subject>Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Epidermal Growth Factor - biosynthesis</subject><subject>Epidermal Growth Factor - genetics</subject><subject>Epiregulin</subject><subject>Gene expression</subject><subject>Gene Knockdown Techniques</subject><subject>Glycoproteins - antagonists & inhibitors</subject><subject>Glycoproteins - biosynthesis</subject><subject>Glycoproteins - genetics</subject><subject>Humans</subject><subject>Intercellular Signaling Peptides and Proteins - biosynthesis</subject><subject>Intercellular Signaling Peptides and Proteins - genetics</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Pyrimidines - pharmacology</subject><subject>Receptor, Epidermal Growth Factor - metabolism</subject><subject>Receptor, Fibroblast Growth Factor, Type 3 - metabolism</subject><subject>Short Communication</subject><subject>Signal Transduction - drug effects</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - pathology</subject><subject>Structure-Activity Relationship</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNpdkUtv1DAUhS0EokNhxxpZSIgNKX5NHhukatQpFZUqle4t23FSj5w42DHQH8T_5IZOS9tVdOLvHp17D0JvKTmihNef9c4cMULZop6hFV1zVtCaVc_RihBSFaRh5AC9SmkHsiF19RIdMCYaKhhboT-bGFIqUp6maFNyYcShwyen20vsXa_GNmE1TNcu2j57N2L4g-30SLa2iPbh9BamOU6uH5UHqMcmjHN0Os8WzwEbO-ffblAaw4xLsxqNxeD1y_m2mG8mi79dHn_Hcx5CjkB7n16jF53yyb7Zfw_R1fbkavO1OL84PdscnxdGCDIX1OquE1RXne4MYYyAbphu6qpuK2GIFh2sbUqtSGkNpwruJphlNWF1VRp-iL7c2k5ZD7Y1FmIrL6cIaeONDMrJxy-ju5Z9-Ck5Z2VZlWDwcW8Qw49s0ywHl5YN1GhDTrJpeEMB5UC-f0LuYFs42D-IirUoGUCfbiGzlBRtdx-FErmUL6F8uZS_KMDfPYx_D9-1DcCHPaCSUb6LcHqX_nPrmpFyXfG_Ysa7KQ</recordid><startdate>20120410</startdate><enddate>20120410</enddate><creator>OLIVERAS-FERRAROS, C</creator><creator>CUFI, S</creator><creator>QUERALT, B</creator><creator>VAZQUEZ-MARTIN, A</creator><creator>MARTIN-CASTILLO, B</creator><creator>DE LLORENS, R</creator><creator>BOSCH-BARRERA, J</creator><creator>BRUNET, J</creator><creator>MENENDEZ, J. A</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120410</creationdate><title>Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells</title><author>OLIVERAS-FERRAROS, C ; CUFI, S ; QUERALT, B ; VAZQUEZ-MARTIN, A ; MARTIN-CASTILLO, B ; DE LLORENS, R ; BOSCH-BARRERA, J ; BRUNET, J ; MENENDEZ, J. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-1ebff41b7fbfc0220ebf92b9878d74c0b4f914c6ba06ec31a20142e2802876c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Amphiregulin</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Cancer research</topic><topic>Cell Survival - drug effects</topic><topic>Cetuximab</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>EGF Family of Proteins</topic><topic>Epidermal growth factor</topic><topic>Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Epidermal Growth Factor - biosynthesis</topic><topic>Epidermal Growth Factor - genetics</topic><topic>Epiregulin</topic><topic>Gene expression</topic><topic>Gene Knockdown Techniques</topic><topic>Glycoproteins - antagonists & inhibitors</topic><topic>Glycoproteins - biosynthesis</topic><topic>Glycoproteins - genetics</topic><topic>Humans</topic><topic>Intercellular Signaling Peptides and Proteins - biosynthesis</topic><topic>Intercellular Signaling Peptides and Proteins - genetics</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Pyrimidines - pharmacology</topic><topic>Receptor, Epidermal Growth Factor - metabolism</topic><topic>Receptor, Fibroblast Growth Factor, Type 3 - metabolism</topic><topic>Short Communication</topic><topic>Signal Transduction - drug effects</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - pathology</topic><topic>Structure-Activity Relationship</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OLIVERAS-FERRAROS, C</creatorcontrib><creatorcontrib>CUFI, S</creatorcontrib><creatorcontrib>QUERALT, B</creatorcontrib><creatorcontrib>VAZQUEZ-MARTIN, A</creatorcontrib><creatorcontrib>MARTIN-CASTILLO, B</creatorcontrib><creatorcontrib>DE LLORENS, R</creatorcontrib><creatorcontrib>BOSCH-BARRERA, J</creatorcontrib><creatorcontrib>BRUNET, J</creatorcontrib><creatorcontrib>MENENDEZ, J. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OLIVERAS-FERRAROS, C</au><au>CUFI, S</au><au>QUERALT, B</au><au>VAZQUEZ-MARTIN, A</au><au>MARTIN-CASTILLO, B</au><au>DE LLORENS, R</au><au>BOSCH-BARRERA, J</au><au>BRUNET, J</au><au>MENENDEZ, J. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>2012-04-10</date><risdate>2012</risdate><volume>106</volume><issue>8</issue><spage>1406</spage><epage>1414</epage><pages>1406-1414</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>These authors contributed equally to this research and are listed in random order.</notes><abstract>In addition to the mutational status of KRAS, the epidermal growth factor receptor (EGFR) ligands amphiregulin (AREG) and epiregulin (EREG) might function as bona fide biomarkers of cetuximab (Ctx) sensitivity for most EGFR-driven carcinomas.
Lentivirus-delivered small hairpin RNAs were employed to specifically reduce AREG or EREG gene expression in wild-type KRAS A431 squamous cell carcinoma cells. Colony-forming assays were used to monitor the impact of AREG and EREG knockdown on Ctx efficacy. Amphiregulin and EREG protein expression levels were assessed by quantitative ELISA in parental A431 cells and in pooled populations of A431 cells adapted to grow in the presence of Ctx. A phosphoproteomic platform was used to measure the relative level of phosphorylation of 42 distinct receptor tyrosine kinases before and after the acquisition of resistance to Ctx.
Stable gene silencing of either ligand was found to notably reduce the expression of the other ligand. Parental A431 cells with normal expression levels of AREG/EREG exhibited significantly increased growth inhibition in response to Ctx, compared with derivatives that are engineered to produce minimal AREG/EREG. The parental A431 cells acutely treated with Ctx exhibited reduced basal expression levels of AREG/EREG. Pooled populations of Ctx-resistant A431 cells expressed significantly lower levels of AREG/EREG and were insensitive to the downregulatory effects of Ctx. Phosphoproteomic screen identified a remarkable hyperactivation of FGFR3 in Ctx-resistant A431 cells, which gained sensitivity to the cytotoxic and apoptotic effects of the FGFR3 TK inhibitor PD173074. The A431 parental cells acutely treated with Ctx rapidly activated FGFR3 and their concomitant exposure to Ctx and PD173074 resulted in synergistic apoptosis.
Cross-suppression of AREG/EREG expression may explain the tight co-expression of AREG and EREG, as well as their tendency to be more highly expressed than other EGFR ligands to determine Ctx efficacy. The positive selection for Ctx-resistant tumour cells exhibiting AREG/EREG cross-suppression may have an important role in the emergence of Ctx resistance. As de-repression of FGFR3 activity rapidly replaces the loss of EGFR-ligand signalling in terms of cell proliferation and survival, combinations of Ctx and FGFR3-targeted drugs may be a valuable strategy to enhance the efficacy of single Ctx while preventing or delaying acquired resistance to Ctx.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>22491422</pmid><doi>10.1038/bjc.2012.103</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2012-04, Vol.106 (8), p.1406-1414 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3326676 |
| source | PubMed Central (PMC) |
| subjects | Amphiregulin Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Antineoplastic Agents - pharmacology Apoptosis - drug effects Biological and medical sciences Biomarkers Cancer research Cell Survival - drug effects Cetuximab Drug Resistance, Neoplasm - drug effects EGF Family of Proteins Epidermal growth factor Epidermal Growth Factor - antagonists & inhibitors Epidermal Growth Factor - biosynthesis Epidermal Growth Factor - genetics Epiregulin Gene expression Gene Knockdown Techniques Glycoproteins - antagonists & inhibitors Glycoproteins - biosynthesis Glycoproteins - genetics Humans Intercellular Signaling Peptides and Proteins - biosynthesis Intercellular Signaling Peptides and Proteins - genetics Kinases Ligands Medical research Medical sciences Metastasis Oncology Pyrimidines - pharmacology Receptor, Epidermal Growth Factor - metabolism Receptor, Fibroblast Growth Factor, Type 3 - metabolism Short Communication Signal Transduction - drug effects Skin Neoplasms - drug therapy Skin Neoplasms - pathology Structure-Activity Relationship Tumor Cells, Cultured Tumors |
| title | Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T17%3A45%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cross-suppression%20of%20EGFR%20ligands%20amphiregulin%20and%20epiregulin%20and%20de-repression%20of%20FGFR3%20signalling%20contribute%20to%20cetuximab%20resistance%20in%20wild-type%20KRAS%20tumour%20cells&rft.jtitle=British%20journal%20of%20cancer&rft.au=OLIVERAS-FERRAROS,%20C&rft.date=2012-04-10&rft.volume=106&rft.issue=8&rft.spage=1406&rft.epage=1414&rft.pages=1406-1414&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2012.103&rft_dat=%3Cproquest_pubme%3E993912663%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c440t-1ebff41b7fbfc0220ebf92b9878d74c0b4f914c6ba06ec31a20142e2802876c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=993145462&rft_id=info:pmid/22491422&rfr_iscdi=true |